Drug Information Update- FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
The Division of Drug Information (DDI) is CDER’s focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The U.S. Food and Drug Administration approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
MS is a chronic, often disabling, disease that affects the central nervous system—the brain, spinal cord, and optic nerves. There are about 400,000 people in the United States and 2.5 million people world-wide with MS.
For more information, please visit: Ampyra
No comments yet.
-
Archives
- August 2013 (1)
- July 2013 (2)
- November 2012 (1)
- September 2012 (3)
- August 2012 (4)
- July 2012 (1)
- April 2012 (4)
- September 2011 (3)
- August 2011 (1)
- July 2011 (3)
- June 2011 (9)
- May 2011 (7)
-
Categories
-
RSS
Entries RSS
Comments RSS
Leave a Reply